Biomarkers for psma targeted therapy for prostate cancer
AssigneePSMA Development Company, LLC
InventorsWILLIAM C. OLSON, VINCENT DIPIPPO
Life of this patent
Estimating the term…
Abstract
Provided herein are a number of methods, assays and diagnostic tests based on one or more biomarkers as well as related kits and compositions that can be used to identify subjects or patients that would likely benefit from a treatment (or continued treatment), such as a PSMA targeted therapy. Also provided are methods for treating the identified subjects or patients.
Claims35
A companion diagnostic test comprising:
- a. obtaining one or more biological samples from a subject undergoing a treatment or considered for a treatment;
- b. assaying a panel of biomarkers;
- c. generating a score with an algorithm based on the assay results of said panel of biomarkers;
- and
- d. determining the likely responsiveness of said subject to said treatment based on the score.
(canceled)
(canceled)
7-9. (canceled)
(canceled)
(canceled)
21-23. (canceled)
(canceled)
(canceled)
31-60. (canceled)
A method of treating metastatic prostate cancer comprising:
- a) performing a biomarker test on a patient at baseline;
- and
- b) providing a treatment to the patient according to the results of the biomarker test.
62-96. (canceled)
A biomarker assay for identifying a subject likely to respond to a PSMA targeted therapy comprising:
- determining the average cell surface PSMA density on PSMA+ CTCs.
98-130. (canceled)
A biomarker assay for identifying a subject likely to respond to a PSMA targeted therapy comprising:
- measuring one or more serum neuroendocrine markers in a sample from a subject.
132-142. (canceled)
A diagnostic kit for selecting a prostate cancer patient for treatment by a PSMA ligand-anticancer agent conjugate, wherein the diagnostic kit comprises;
- assay reagents to measure serum levels of neuroendocrine enzymes and instructions for selecting;
- reagents for use in an biomarker assay to determine the PSMA density on PSMA+ CTCs in a biological sample obtained from the patient, and instructions for selecting;
- or
- reagents for use in an IHC assay to determine the H-score of a biological sample obtained from the patient, and instructions for selecting.
144-161. (canceled)
Dependencies are inferred from the claim text.